Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the
“Company”), a clinical stage biotechnology company discovering and
developing novel antiviral therapeutics, today announced that
its poster demonstrating positive data from its triple regimen,
U.S. Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir
(Epclusa) for the ultra-short treatment of HCV infected individuals
was selected for presentation at the American Association for the
Study of Liver Diseases (AASLD) 2019 Liver Meeting being held
November 8-12, 2019 in Boston, MA.
“We are pleased to be presenting this positive
data at the AASLD 2019 meeting. There remains a major global
barrier in the treatment of chronic HCV with the high cost of
currently approved combination direct-acting antiviral (DAA)
therapy of 8- and 12-weeks duration. CC-31244 seeks to provide a
shorter duration therapy that maintains the high cure rates of
currently available therapy, ultimately reducing the cost and
improving adherence. We are encouraged by the data presented in our
poster which suggests that we can identify the patients that are
more likely to respond to our shorter treatment and look forward to
advancing the development of ultrashort duration HCV therapy,”
commented Dr. Sam Lee, President of Cocrystal.
Joel Chua, MD, Assistant Professor of Medicine
of the Institute of Human Virology at the University of Maryland
School of Medicine and Principal Investigator of the trial
commented, “CD8+ effector T cell phenotypes are associated with
virological cure when given in combination with CC-31244 and
SOF/VEL in adults with chronic HCV. Identifying these select
patients is the key to clinical development of ultrashort duration
HCV therapy."
The details for the Company’s poster
presentation are as follows:
Presenting Author: Joel Chua, MD
Abstract Title: Immune Cell
Phenotypes Associated with Successful Response to 2 Weeks of a
Novel Non-Nucleoside Inhibitor CDI-31244 Concurrent with 6 Weeks of
Sofosbuvir/Velpatasvir in Subjects with Chronic Hepatitis C
Genotype 1 Infection. Poster 1673Presentation
Date: Sunday, November 10,
2019Presentation Time: 8:00 AM – 5:00 PM ET
For additional information about
the U.S. Phase 2a study of CC-31244 for the treatment of
viral hepatitis C, please visit ClinicalTrials.gov and
reference identifier NCT03501550.
About the AASLD 2019 Liver
Meeting
AASLD is the leading organization of scientists
and health care professionals committed to preventing and curing
liver disease. AASLD was founded in 1950 by a small group of
leading liver specialists (including Hans Popper, Leon Schiff, Fred
Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock, to
name a few) to bring together those who had contributed to the
field of hepatology.
The annual AASLD Liver Meeting has grown to an
international society responsible for all aspects of hepatology,
and our annual meeting, AASLD, has grown in attendance from 12 to
more than 12,500 physicians, surgeons, researchers, and allied
health professionals from around the world. For more information,
please visit the conference website.
About CC-31244
CC-31244 is an investigational, oral,
broad-spectrum replication inhibitor called a non-nucleoside
inhibitor (NNI). It has been designed and developed using the
Company's proprietary structure-based drug discovery technology to
have a high barrier to drug resistance and to be a highly potent,
selective NNI that is active against all HCV genotypes (1-6) with
low level cytotoxicity in multiple cell types.
About Cocrystal Pharma,
Inc.
Cocrystal Pharma, Inc. is a clinical stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication machinery of influenza
viruses, hepatitis C viruses, and noroviruses. Cocrystal employs
unique structure-based technologies and Nobel Prize winning
expertise to create first- and best-in-class antiviral drugs. The
Company is developing CC-31244, an investigational, oral,
broad-spectrum replication inhibitor called a non-nucleoside
inhibitor (NNI). CC-31244 is currently being evaluated in a Phase
2a study for the treatment of hepatitis C as part of a cocktail for
ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered
into an exclusive worldwide license and collaboration agreement
with Merck & Co., Inc. to discover and develop certain
proprietary influenza A/B antiviral agents. CC-42344, the Company’s
molecule for the treatment of influenza A, is currently being
evaluated in preclinical IND-enabling studies. In addition, the
Company has a pipeline of promising early preclinical programs and
continues to identify and develop novel antivirals for the
treatment of norovirus gastroenteritis using the Company’s
proprietary structure-based drug design technology platform. For
further information about Cocrystal, please visit
www.cocrystalpharma.com.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including the prospects for advancing the development of ultrashort
duration HCV therapy, the prospects for CC-31244 and CC-42344 and
the Company’s pipeline of promising preclinical programs. The words
"believe," "may," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "could," "target," "potential," "is likely,"
"will," "expect" and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events. Some or all of
the events anticipated by these forward-looking statements may not
occur. Important factors that could cause actual results to differ
from those in the forward-looking statements include, but are not
limited to, risks arising from our reliance on continuing
collaboration with Merck under the collaboration agreement, the
availability of products manufactured by third parties, the future
results of preclinical and clinical studies, the research
organization’s inability to recruit subjects and complete the Phase
2a study in a timely manner or at all, including as the result of
civil unrest and political instability in Hong Kong, general risks
arising from clinical trials, receipt of regulatory approvals, our
ability to find and enter into agreements with suitable
collaboration partners, unanticipated litigation and other expenses
and factors that affect the capital markets in general and early
stage biotechnology companies specifically. Further information on
our risk factors is contained in our filings with the SEC,
including our Annual Report on Form 10-K for the year ended
December 31, 2018 and the Form 10-Q for the quarter ended June 30,
2019. Any forward-looking statement made by us herein speaks only
as of the date on which it is made. Factors or events that could
cause our actual results to differ may emerge from time to time,
and it is not possible for us to predict all of them. We undertake
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by law.
Investor and Media
Contact:Jenene Thomas Communications, LLC(833)
475-8247COCP@jtcir.com
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Sep 2023 to Sep 2024